Literature DB >> 16621406

Applying biofluid 1H NMR-based metabonomic techniques to distinguish between HIV-1 positive/AIDS patients on antiretroviral treatment and HIV-1 negative individuals.

R Hewer1, J Vorster, F E Steffens, D Meyer.   

Abstract

Metabonomics, the study of metabolites and their role in various physiological states, is a novel methodology arising from the post-genomics era and has extensive biomedical application. This technology has exhibited vast success in the identification and study of human diseases and may find further application in the study of HIV/AIDS. Specifically, the wide range of clinical and metabolic abnormalities associated with the use of antiretroviral (ARV) treatment may be investigated. To this end, this preliminary study evaluated whether metabonomic techniques could distinguish between HIV-1 positive/AIDS patients utilizing antiretroviral therapy and HIV-1 negative individuals. Serum metabolic profiles determined by 1H nuclear magnetic resonance (NMR) spectroscopy combined with pattern recognition analysis of the data showed that this distinction was attainable; suggesting that ARV-associated side-effects could be monitored utilizing NMR metabonomic techniques.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621406     DOI: 10.1016/j.jpba.2006.03.006

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  13 in total

Review 1.  Metabolomics: moving to the clinic.

Authors:  Anders Nordström; Rolf Lewensohn
Journal:  J Neuroimmune Pharmacol       Date:  2009-04-28       Impact factor: 4.147

2.  Comparative 1H NMR-based metabonomic analysis of HIV-1 sera.

Authors:  C Philippeos; F E Steffens; D Meyer
Journal:  J Biomol NMR       Date:  2009-06-10       Impact factor: 2.835

3.  A combined chemometric and quantitative NMR analysis of HIV/AIDS serum discloses metabolic alterations associated with disease status.

Authors:  Tracy R McKnight; Hikari A I Yoshihara; Lungile J Sitole; Jeffery N Martin; Francois Steffens; Debra Meyer
Journal:  Mol Biosyst       Date:  2014-11

4.  Mid-ATR-FTIR spectroscopic profiling of HIV/AIDS sera for novel systems diagnostics in global health.

Authors:  Lungile Sitole; Francois Steffens; Tjaart P J Krüger; Debra Meyer
Journal:  OMICS       Date:  2014-06-17

5.  Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection.

Authors:  Shiek Ssj Ahmed; Winkins Santosh; Suresh Kumar; Hema T Thanka Christlet
Journal:  J Biomed Sci       Date:  2009-07-13       Impact factor: 8.410

6.  Serum metabolomics analysis of patients with chikungunya and dengue mono/co-infections reveals distinct metabolite signatures in the three disease conditions.

Authors:  Jatin Shrinet; Jayanthi S Shastri; Rajni Gaind; Neel Sarovar Bhavesh; Sujatha Sunil
Journal:  Sci Rep       Date:  2016-11-15       Impact factor: 4.379

7.  Serum Metabolic Profile Alteration Reveals Response to Platinum-Based Combination Chemotherapy for Lung Cancer: Sensitive Patients Distinguished from Insensitive ones.

Authors:  Shan Xu; Yanping Zhou; Hui Geng; Dandan Song; Jing Tang; Xianmin Zhu; Di Yu; Sheng Hu; Yanfang Cui
Journal:  Sci Rep       Date:  2017-12-13       Impact factor: 4.379

8.  A novel R-package graphic user interface for the analysis of metabonomic profiles.

Authors:  Jose L Izquierdo-García; Ignacio Rodríguez; Angelos Kyriazis; Palmira Villa; Pilar Barreiro; Manuel Desco; Jesús Ruiz-Cabello
Journal:  BMC Bioinformatics       Date:  2009-10-29       Impact factor: 3.169

Review 9.  Metabolomics in infectious diseases and drug discovery.

Authors:  Vivian Tounta; Yi Liu; Ashleigh Cheyne; Gerald Larrouy-Maumus
Journal:  Mol Omics       Date:  2021-06-14

10.  Nuclear magnetic resonance based profiling of biofluids reveals metabolic dysregulation in HIV-infected persons and those on anti-retroviral therapy.

Authors:  Saif Ullah Munshi; Bharat Bhushan Rewari; Neel Sarovar Bhavesh; Shahid Jameel
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.